Miami, Florida– Global Stem Cells Group (GSCG), an established international organization focused on advancing regenerative medicine, is pleased to announce a new strategic collaboration with the Njinsky Medical Centre for the exclusive launch of its CELLGENIC product line in Pakistan. This collaboration represents a significant milestone in what both parties hope will be the broader introduction of regenerative technologies across South Asia and the Middle East.
Through this alliance, the Njinsky Medical Centre will serve as the exclusive distributor of CELLGENIC-branded exosome products in Pakistan, a country recognized as one of the most populous and dynamic healthcare markets in the region. Both organizations are committed to a shared vision: to explore opportunities for innovation, improve accessibility to emerging therapies, and support the responsible and ethical application of regenerative medicine technologies.
A Collaborative Framework for Long-Term Development
The five-year distribution agreement outlines a coordinated rollout strategy that includes the introduction of CELLGENIC’s full regenerative medicine product portfolio. The agreement also provides for the development of multiple stem cell and regenerative treatment centers across the country, the organization of four physician training sessions annually, and the establishment of an international medical congress in Pakistan focused on education and awareness in the field of cellular therapies.
“We believe this collaboration may offer a sustainable and scalable model for bringing scientifically grounded regenerative solutions to new markets,” said Benito Novas, CEO of Global Stem Cells Group and founder of CELLGENIC. “Through strategic alignment with local institutions like the Njinsky Medical Centre, we hope to support healthcare professionals by expanding access to training and emerging technologies.”
The CELLGENIC Portfolio: A Platform for Innovation
As part of the agreement, the Njinsky Medical Centre will receive access to the complete CELLGENIC product range, including lyophilized and liquid-form exosome therapies. These formulations, developed by GSCG through international research and quality-controlled processes, are based on exosomes derived from human umbilical cord stem cells and are produced in accordance with established industry standards.
While results may vary depending on the clinical application, exosomes are being explored for their potential role in supporting tissue regeneration, managing inflammatory conditions, and contributing to overall cellular communication. CELLGENIC’s products are currently offered for investigational and physician-directed use in countries with relevant regulatory frameworks that allow their application.
Key product features include:
- Sourced from human umbilical cord-derived MSCs
- Available in both liquid and lyophilized (freeze-dried) formulations
- Manufactured under rigorous quality assurance protocols
- Intended for use in professional medical settings under clinical guidance
Njinsky Medical Centre’s Commitment to Local Advancement
As part of the implementation plan, the Njinsky Medical Centre will oversee efforts to meet Pakistan’s regulatory and patient safety standards, while aiming to localize certain stages of production. These efforts are intended to align with national healthcare priorities and ensure the ethical and secure handling of all biological materials.
“We are honored to collaborate with Global Stem Cells Group and to take part in introducing these technologies to our region,” said Syed Asad Ali, Chief Executive at Njinsky Medical Centre. “This agreement provides us with access to training programs, certifications, and a product platform that we hope will support Pakistani healthcare professionals in offering advanced, research-driven options to their patients.”
Njinsky’s long-term goal includes the expansion of CELLGENIC’s presence across Pakistan, and the integration of GSCG’s broader business lines—ranging from biologics to medical equipment and physician training.
Usman Shah, Managing Partner of Njinsky Medical Centre, added: “We expect this collaboration to serve as a gateway for growth, research, and the integration of regenerative care into clinical practice, in ways that are both cost-conscious and medically responsible.”
Structured Rollout and Training Initiatives
The official launch of the CELLGENIC product line in Pakistan is anticipated for August 2025, with preliminary activities already underway. These include a series of pilot programs and ISSCA-certified training sessions for selected healthcare professionals. The International Society for Stem Cell Application (ISSCA), the educational division of GSCG, will oversee physician training as part of its continuing education initiatives.
Key upcoming milestones include:
- ISSCA Training Programs – Hands-on certification sessions for Pakistani physicians
- Pilot Program Implementation – Initial clinical protocols rolled out in selected centers
- Official Launch Event – High-level medical gathering scheduled for August 2025
- Regional Outreach – Exploration of expansion opportunities in neighboring markets
Through these initiatives, both organizations seek to lay the foundation for a robust and sustainable regenerative medicine ecosystem in Pakistan, one that may serve as a reference model for future regional partnerships.
About Global Stem Cells Group and CELLGENIC
Founded in 2010 and headquartered in Miami, USA, Global Stem Cells Group (GSCG) is a multi-division biotechnology company with a presence in more than 40 countries. As an international consortium, the company is dedicated to stem cell research, physician education, clinical research, and the commercialization of advanced regenerative products.
The organization brings together several specialized companies under one umbrella to offer innovative patient treatment protocols, hands-on training programs, and regulatory consulting. Its flagship brand, CELLGENIC, includes a broad range of biologic solutions—from exosomes to stem cell kits, collagenase systems, and platelet-rich plasma (PRP) kits—developed to support physicians in the evolving field of regenerative healthcare.
GSCG is committed to expanding access to regenerative medicine worldwide and supports physicians through certification programs, conferences, and scientific collaboration.
Global Stem Cells Group is a publicly traded company operating under the symbol RMTG. https://finance.yahoo.com/quote/RMTG/
More information: www.stemcellsgroup.com | www.issca.us
About the Njinsky Medical Centre
The Njinsky Medical Centre (also known as the Njinsky Stem Cell Centre) is a Pakistan-based institution dedicated to investigating and applying stem cell and exosome therapies for complex and chronic conditions. With ISO 9001 (Quality Management Systems), ISO 14644 (Cleanroom Standards), ISO 15189 (Medical Laboratory Standards), International Accreditation Forum (IAF), and Institute of Global Certification (IGC), offering globally recognized excellence in regenerative medicine. Njinsky has a GMP compliant ISO-certified, biosafety level-2 laboratories and a team of licensed medical professionals, the Medical Centre operates at the intersection of clinical practice and global research. Njinsky’s mission is to responsibly introduce the most promising international therapies to the local context, supporting recovery and quality of life for patients where conventional treatments may offer limited results.
More information: www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
